BackImmunoPrecise Antibodies Overview

ImmunoPrecise Antibodies Total Revenue

Track ImmunoPrecise Antibodies's total revenue ($18M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$4.09M
33.5% YoY

As of Jan 2026

Annual Revenue (TTM)

$18.40M
23.34% YoY

Trailing 12 months ending Jan 2026

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

ImmunoPrecise Antibodies (IPA) FAQ

ImmunoPrecise Antibodies's total revenue stands at $18M as of January 2026. That compares with $24M in the prior-year period — down 23.3% year over year. That is below the Healthcare sector average of $110B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

ImmunoPrecise Antibodies reported $18M in total revenue versus $24M a year earlier — a 23.3% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

ImmunoPrecise Antibodies sits lower the Healthcare benchmark ($110B) with a total revenue of $18M. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $24M in the prior-year period — down 23.3% year over year. Sustained growth in total revenue can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how ImmunoPrecise Antibodies's total revenue evolved across reporting periods, while the comparison chart places IPA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.